查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
乾眼症治療 - 全球行業規模、份額、趨勢、機遇和預測，2018-2028 年：按適應症、按產品類型、按配方、按類型、按分銷渠道、按地區、按競爭
市場調查報告書
商品編碼
1255239

乾眼症治療 - 全球行業規模、份額、趨勢、機遇和預測，2018-2028 年：按適應症、按產品類型、按配方、按類型、按分銷渠道、按地區、按競爭

Dry Eye Syndrome Treatment - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Indication, By Product Type, By Dosage Form, By Type, By Distribution Channel, By Region, and Competition
出版日期: | 出版商: TechSci Research | 英文 111 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

在預測期內，乾眼症治療的全球市場預計將出現顯著增長。

這是由於某些疾病（例如類風濕性關節炎、甲狀腺疾病和狼瘡）導致全球乾眼症的患病率不斷上升。 此外，新眼藥水的批准和上市增加，醫療保健領域為開髮乾眼病新療法而增加的研發活動也有望在預測期內進一步支持乾眼症治療市場的增長。 美國有超過12萬人因青光眼失明，佔失明病例的9%至12%。 此外，增加成人淚液產生的鼻內淚腺神經刺激器的開發正在取得進展，預計隨著新療法的開發，這將在預測期內推動市場增長。 此外，隨著監管審批的增加，市場新進入者的增加預計將進一步推動市場增長。

乾眼症患病率增加

最常見的干眼病是一種慢性眼科疾病，與成年人相比，它在老年人群中的患病率更高。 屏幕使用頻率增加、飲食攝入不當、隱形眼鏡使用頻率增加以及全球 LASIK 手術數量增加將進一步推動預測期內的市場增長。 隨著年齡的增長，淚腺產生淚液的能力下降，導致乾眼症，導致對乾眼症的需求，並成為預測期內推動市場增長的關鍵因素之一。。 根據國家健康與健康調查的數據，6.8% 的美國成年人（約 1640 萬人）被診斷出患有 DED。

加大對醫療保健行業的投資

此外，增加公共和私營部門的舉措以傳播對乾眼症新療法的認識，這將推動干眼症治療市場多年發展。 飲食習慣和久坐不動的生活方式的改變是影響預測期內市場動態的因素。 全球眼科護理中心的發展以及 OTC 眼藥水市場在發展中地區的滲透率不斷提高，將進一步推動預測期內的市場增長。 2022年1月，Sun Pharma宣布將在加拿大推出名為Cequa的干眼症治療產品。 這是第一種使用納米膠束 (NCELL) 技術進行的干眼病治療。 該技術不僅提高了環孢菌素的生物利用度，還提高了理化穩定性和對眼組織的滲透性。

近期發展

  • 2019 年 10 月，Sun Pharmaceutical Industries Ltd 在美國推出了乾眼症治療藥物 CEQUA，是美國 FDA 批准的最高濃度眼用環孢菌素。
  • 2019 年 7 月 Novartis是第一個也是唯一一個獲批通過控制干眼症特異性炎症來治療乾眼症症狀和體徵的處方藥。宣布成功收購 Xiidra 5%

可自定義

根據市場數據，TechSci Research 根據公司的具體需求提供定制服務。 該報告可以定制為：

公司信息

  • 對其他市場參與者（最多 5 家公司）進行深入分析和概況分析。

內容

第 1 章概述

  • 市場定義
  • 市場範圍
    • 目標市場
    • 研究目標年份
    • 主要市場細分

第二章研究方法論

  • 調查目的
  • 基線調查方法
  • 主要行業合作夥伴
  • 主要協會和次要信息
  • 調查方法
  • 數據三角測量和驗證
  • 假設和限制

第 3 章執行摘要

  • 市場概覽
  • 主要市場細分概述
  • 主要市場參與者概覽
  • 主要地區/國家概覽
  • 市場驅動因素、挑戰和趨勢

第 4 章 VOC（客戶之聲）

第5章臨床試驗分析

  • 正在進行的臨床試驗
  • 已完成臨床試驗
  • 已完成臨床試驗
  • 管道細分（按開發階段）
  • 管道細分（按狀態）
  • 管道細分（按研究類型）
  • 按地區劃分的渠道細分
  • 臨床試驗熱圖

第 6 章乾眼症治療的全球市場展望

  • 市場規模和預測
    • 按數量
  • 市場份額和預測
    • 根據適應症（蒸發過強性乾眼症/房水性乾眼症）
    • 按產品類型（環孢菌素、皮質類固醇、人工淚液、穿刺塞等）
    • 按劑型（凝膠劑、眼藥水、膠囊/片劑、滴眼劑、軟膏）
    • 按類型（處方藥/非處方藥）
    • 按分銷渠道（醫院藥店、零售藥店、在線藥店）
    • 按地區
    • 按公司分類（2022 年）
  • 市場地圖
    • 按視圖
    • 按產品類型
    • 按劑型
    • 按類型
    • 按分銷渠道
    • 按地區

第 7 章北美乾眼症治療市場展望

  • 市場規模和預測
    • 按數量
  • 市場份額和預測
    • 按視圖
    • 按產品類型
    • 按劑型
    • 按類型
    • 按分銷渠道
    • 按國家
  • 北美：國家/地區分析
    • 美國
    • 加拿大
    • 墨西哥

第 8 章歐洲乾眼症治療市場展望

  • 市場規模和預測
    • 按數量
  • 市場份額和預測
    • 按視圖
    • 按產品類型
    • 按劑型
    • 按類型
    • 按分銷渠道
    • 按國家
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 意大利
    • 西班牙

第 9 章亞太乾眼症治療市場展望

  • 市場規模和預測
    • 按數量
  • 市場份額和預測
    • 按視圖
    • 按產品類型
    • 按劑型
    • 按類型
    • 按分銷渠道
    • 按國家
  • 亞太地區：國家/地區分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳大利亞

第 10 章南美乾眼症治療市場展望

  • 市場規模和預測
    • 按數量
  • 市場份額和預測
    • 按視圖
    • 按產品類型
    • 按劑型
    • 按類型
    • 按分銷渠道
    • 按國家
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 11 章中東和非洲乾眼症治療市場展望

  • 市場規模和預測
    • 按數量
  • 市場份額和預測
    • 按視圖
    • 按產品類型
    • 按劑型
    • 按類型
    • 按分銷渠道
    • 按國家
  • MEA：國家分析
    • 南非的干眼症治療
    • 沙特阿拉伯的干眼症治療
    • 阿聯酋乾眼症治療

第 12 章市場動態

  • 司機
  • 任務

第13章市場趨勢與發展

  • 近期趨勢
  • 併購
  • 產品發布

第14章競爭格局

  • Johnson & Johnson
  • AbbVie Inc.
  • Bausch Health Companies Inc.
  • Novartis AG
  • Sun Pharmaceuticals Industries Limited
  • Santen Pharmaceutical Co., Ltd.
  • Otsuka Pharmaceutical Co., Ltd.
  • Oyster Point Pharma, Inc.
  • Alcon Inc.
  • GlaxoSmithKline plc.

第 15 章戰略建議

簡介目錄
Product Code: 14428

The Global Dry Eye Syndrome Treatment Market is anticipated to witness impressive growth during the forecast period. This can be ascribed to the growing prevalence of dry eye syndrome due to certain diseases, such as rheumatoid arthritis, thyroid diseases, and lupus, across the globe. Besides, increasing drug approvals and launches of new eye drops, along with rising research and development activities in the healthcare sector for the development of new treatments for dry eye diseases across the globe, are further expected to support the dry eye syndrome treatment market during the forecast period. In the U.S., more than 120,000 are blind from glaucoma, accounting for 9% to 12% of all cases of blindness. Also, the growing development of intranasal tear neurostimulation devices, which will increase tear production in adults, along with the development of new treatment modalities, will boost the market growth during the forecasted period. Also, the rising number of new players in the market is anticipated to lead the regulatory approvals and further propel the growth of the market.

Growing Prevalence of Dry Eye Disease

The most common dry eye disease is a chronic ophthalmic disorder which has a high prevalence rate among the aging population compared to adults. Growing usage of screens, consuming improper diet, growing usage of contact lenses, and the rising number of LASIK surgeries across the globe will further drive the market growth in the forecast period. Due to increasing age, the ability of the lachrymal glands to produce tears decreases, which leads to a dry eye condition which is one of the key factors contributing to the demand for dry eye syndrome and driving the growth of the market during the forecasted period. Based on data from the National Health and Wellness Survey, 6.8 percent of the United States adult population (approximately 16.4 million people) have been diagnosed with DED.

Growing investment in Healthcare Industry

Furthermore, growing initiatives by public and private organizations to spread awareness about the new treatment of dry eye syndrome will propel the dry eye syndrome treatment market over the years. Changing dietary patterns and sedentary lifestyles are the factors that will influence the market dynamics during the forecast period. Increasing the number of eye care centers across the globe and growing penetration of the OTC eyedrop market across developing regions will further boost the market growth in the forecast period. In January 2022, Sun Pharma announced the launch of a dry eye treatment product named Cequa in Canada. It is the first dry eye disease treatment that is delivered with nano micellar (NCELL) technology. This technology enhances the bioavailability as well as physiochemical stability of cyclosporine to raise ocular tissue penetration.

Market Segmentation

The Global Dry Eye Syndrome Treatment Market can be segmented by indication, product type, dosage form, type, distribution channel, and by region. Based on indication, the market can be divided into Evaporative Dry Eye Syndrome and Aqueous Deficient Dry Eye Syndrome. Based on product type, the market can be differentiated into Cyclosporine, Topical Corticosteroids, Artificial Tears, Punctal Plugs, and Others. Based on dosage form, the market can be grouped into Gels, Eye Solutions, Capsules & Tablets, Eye Drops, and Ointments. Based on Type, the market can be divided into Prescription and Over Counter. Based on distribution channels, the market can be segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Regionally, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, the United States dominated the global dry eye syndrome treatment market on account of the growing demand for dry eye treatment in the country.

Recent Developments

  • In October 2019, Sun Pharmaceutical Industries Ltd launched a product called CEQUA for the treatment of dry eye syndrome in the U.S. and the highest concentration of cyclosporine for ophthalmic use, which is approved by the U.S. FDA.
  • In July 2019, Novartis announced the completion of the successful acquisition of Xiidra 5%, the first and only prescription treatment approved to treat both signs and symptoms of dry eye by controlling the inflammation caused by the disease.

Market Players

Johnson & Johnson, AbbVie Inc., Bausch Health Companies Inc., Novartis AG, Sun Pharmaceuticals Industries Limited, Santen Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Oyster Point Pharma, Inc., Alcon Inc., GlaxoSmithKline plc. are some of the leading players operating in the Global Dry Eye Syndrome Treatment Market.

Report Scope

In this report, global dry eye syndrome treatment market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Dry Eye Syndrome Treatment Market, By Indication:

  • Evaporative Dry Eye Syndrome
  • Aqueous Deficient Dry Eye Syndrome

Dry Eye Syndrome Treatment Market, By Product Type:

  • Cyclosporine
  • Topical Corticosteroids
  • Artificial Tears
  • Punctal Plugs
  • Others

Dry Eye Syndrome Treatment Market, By Dosage Form:

  • Gels
  • Eye Solutions
  • Capsules & Tablets
  • Eye Drops
  • Ointments

Dry Eye Syndrome Treatment Market, By Type:

  • Prescription
  • Over The Counter

Dry Eye Syndrome Treatment Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Dry Eye Syndrome Treatment Market, By Region:

  • North America
    • United States
    • Mexico
    • Canada
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Dry Eye Syndrome Treatment Market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Type
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Global Dry Eye Syndrome Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication (Evaporative Dry Eye Syndrome v/s Aqueous Deficient Dry Eye Syndrome)
    • 6.2.2. By Product Type (Cyclosporine, Topical Corticosteroids, Artificial Tears, Punctal Plugs, Others)
    • 6.2.3. By Dosage Form (Gels, Eye Solutions, Capsules & Tablets, Eye Drops, Ointments)
    • 6.2.4. By Type (Prescription v/s Over The Counter)
    • 6.2.5. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 6.2.6. By Region
    • 6.2.7. By Company (2022)
  • 6.3. Market Map
    • 6.3.1. By Indication
    • 6.3.2. By Product Type
    • 6.3.3. By Dosage Form
    • 6.3.4. By Type
    • 6.3.5. By Distribution Channel
    • 6.3.6. By Region

7. North America Dry Eye Syndrome Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Product Type
    • 7.2.3. By Dosage Form
    • 7.2.4. By Type
    • 7.2.5. By Distribution Channel
    • 7.2.6. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Dry Eye Syndrome Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By Product Type
        • 7.3.1.2.3. By Dosage Form
        • 7.3.1.2.4. By Type
        • 7.3.1.2.5. By Distribution Channel
    • 7.3.2. Canada Dry Eye Syndrome Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By Product Type
        • 7.3.2.2.3. By Dosage Form
        • 7.3.2.2.4. By Type
        • 7.3.2.2.5. By Distribution Channel
    • 7.3.3. Mexico Dry Eye Syndrome Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By Product Type
        • 7.3.3.2.3. By Dosage Form
        • 7.3.3.2.4. By Type
        • 7.3.3.2.5. By Distribution Channel

8. Europe Dry Eye Syndrome Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Product Type
    • 8.2.3. By Dosage Form
    • 8.2.4. By Type
    • 8.2.5. By Distribution Channel
    • 8.2.6. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Dry Eye Syndrome Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Product Type
        • 8.3.1.2.3. By Dosage Form
        • 8.3.1.2.4. By Type
        • 8.3.1.2.5. By Distribution Channel
    • 8.3.2. Germany Dry Eye Syndrome Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Product Type
        • 8.3.2.2.3. By Dosage Form
        • 8.3.2.2.4. By Type
        • 8.3.2.2.5. By Distribution Channel
    • 8.3.3. United Kingdom Dry Eye Syndrome Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Product Type
        • 8.3.3.2.3. By Dosage Form
        • 8.3.3.2.4. By Type
        • 8.3.3.2.5. By Distribution Channel
    • 8.3.4. Italy Dry Eye Syndrome Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Indication
        • 8.3.4.2.2. By Product Type
        • 8.3.4.2.3. By Dosage Form
        • 8.3.4.2.4. By Type
        • 8.3.4.2.5. By Distribution Channel
    • 8.3.5. Spain Dry Eye Syndrome Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Indication
        • 8.3.5.2.2. By Product Type
        • 8.3.5.2.3. By Dosage Form
        • 8.3.5.2.4. By Type
        • 8.3.5.2.5. By Distribution Channel

9. Asia-Pacific Dry Eye Syndrome Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Product Type
    • 9.2.3. By Dosage Form
    • 9.2.4. By Type
    • 9.2.5. By Distribution Channel
    • 9.2.6. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Dry Eye Syndrome Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Product Type
        • 9.3.1.2.3. By Dosage Form
        • 9.3.1.2.4. By Type
        • 9.3.1.2.5. By Distribution Channel
    • 9.3.2. India Dry Eye Syndrome Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Product Type
        • 9.3.2.2.3. By Dosage Form
        • 9.3.2.2.4. By Type
        • 9.3.2.2.5. By Distribution Channel
    • 9.3.3. Japan Dry Eye Syndrome Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Product Type
        • 9.3.3.2.3. By Dosage Form
        • 9.3.3.2.4. By Type
        • 9.3.3.2.5. By Distribution Channel
    • 9.3.4. South Korea Dry Eye Syndrome Treatment Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Indication
        • 9.3.4.2.2. By Product Type
        • 9.3.4.2.3. By Dosage Form
        • 9.3.4.2.4. By Type
        • 9.3.4.2.5. By Distribution Channel
    • 9.3.5. Australia Dry Eye Syndrome Treatment Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Indication
        • 9.3.5.2.2. By Product Type
        • 9.3.5.2.3. By Dosage Form
        • 9.3.5.2.4. By Type
        • 9.3.5.2.5. By Distribution Channel

10. South America Dry Eye Syndrome Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Product Type
    • 10.2.3. By Dosage Form
    • 10.2.4. By Type
    • 10.2.5. By Distribution Channel
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Dry Eye Syndrome Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By Product Type
        • 10.3.1.2.3. By Dosage Form
        • 10.3.1.2.4. By Type
        • 10.3.1.2.5. By Distribution Channel
    • 10.3.2. Argentina Dry Eye Syndrome Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By Product Type
        • 10.3.2.2.3. By Dosage Form
        • 10.3.2.2.4. By Type
        • 10.3.2.2.5. By Distribution Channel
    • 10.3.3. Colombia Dry Eye Syndrome Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
        • 10.3.3.2.2. By Product Type
        • 10.3.3.2.3. By Dosage Form
        • 10.3.3.2.4. By Type
        • 10.3.3.2.5. By Distribution Channel

11. Middle East and Africa Dry Eye Syndrome Treatment Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Indication
    • 11.2.2. By Product Type
    • 11.2.3. By Dosage Form
    • 11.2.4. By Type
    • 11.2.5. By Distribution Channel
    • 11.2.6. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Dry Eye Syndrome Treatment Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Indication
        • 11.3.1.2.2. By Product Type
        • 11.3.1.2.3. By Dosage Form
        • 11.3.1.2.4. By Type
        • 11.3.1.2.5. By Distribution Channel
    • 11.3.2. Saudi Arabia Dry Eye Syndrome Treatment Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Indication
        • 11.3.2.2.2. By Product Type
        • 11.3.2.2.3. By Dosage Form
        • 11.3.2.2.4. By Type
        • 11.3.2.2.5. By Distribution Channel
    • 11.3.3. UAE Dry Eye Syndrome Treatment Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Indication
        • 11.3.3.2.2. By Product Type
        • 11.3.3.2.3. By Dosage Form
        • 11.3.3.2.4. By Type
        • 11.3.3.2.5. By Distribution Channel

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Developments
  • 13.2. Mergers & Acquisitions
  • 13.3. Product Launches

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Product Offerings
  • 14.3. Recent Developments
  • 14.4. Financials (As Reported)
  • 14.5. Key Personnel
  • 14.6. SWOT Analysis
    • 14.6.1. Johnson & Johnson
    • 14.6.2. AbbVie Inc.
    • 14.6.3. Bausch Health Companies Inc.
    • 14.6.4. Novartis AG
    • 14.6.5. Sun Pharmaceuticals Industries Limited
    • 14.6.6. Santen Pharmaceutical Co., Ltd.
    • 14.6.7. Otsuka Pharmaceutical Co., Ltd.
    • 14.6.8. Oyster Point Pharma, Inc.
    • 14.6.9. Alcon Inc.
    • 14.6.10. GlaxoSmithKline plc.

15. Strategic Recommendations